

According to the Paperwork Reduction Act of 1995, an agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0579-0036. The time required to complete this information collection is estimated to average 2 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.

OMB APPROVED 0579-0036

This report is required by law (7 USC 2143). Failure to report according to the regulations can result in an order to cease and desist and to be subject to penalties as provided for in Section 2150

Interagency Report Control No 0180-DOA-AN

Fiscal Year: 2009

UNITED STATES DEPARTMENT OF AGRICULTURE ANIMAL AND PLANT HEALTH INSPECTION SERVICE

ANNUAL REPORT OF RESEARCH FACILITY

(TYPE OR PRINT)

REGISTRATION NUMBER: 57-R-0003

Customer Number:

2. HEADQUARTERS RESEARCH FACILITY (Name and Address as registered with USDA

Emory University Woodruff Hith Sciences Ctr, 1440 Clifton Rd Ne

Atlanta, GA 30322

Telephone: (404) 727 3889

3. REPORTING FACILITY (List all locations where animals were housed or used in actual research, testing, teaching, or experimentation, or held for these purposes. Attach additional sheets if FACILITY LOCATIONS (Sites) See Attached Listing

REPORT OF ANIMALS USED BY OR UNDER CONTROL OF RESEARCH FACILITY (Attach additional sheets if necessary or use APHIS FORM 7023A) Number of animals upon which teaching Number of animal upor which experiments experiments, research, surgery or tests were teaching, research, surgery, or tests were conducted involving conducted involving accompanying pain or distress to the animals and for which the use of appropriate anesthetic, analgesic, or Number of animals being bred, Number of animals Animals Covered By conditioned, or held teaching, research, TOTAL NUMBER for use in teaching, testing, experiments, research, or surgery but not yet used for accompanying pain or distress to the animals and for which The Animal experiments, or tranquilizing drugs would have adversely OF ANIMALS tests were conducted involving affected the procedures, results, or interpretation of the teaching, research, experiments, surgery, or tests. (An explanation Welfare Regulations (Cols. C+D+E) appropriate anesthetic, no pain, distress, or analgesic, or tranquilizing drugs were of the procedures producing pain or distress in these animals and the reasons such drugs were not used must be attached to this report) such purposes. use of pain-relieving drugs. 19 0 2 17 0 4. Dogs 0 0 0 0 0 5. Cats 100 273 390 6. Guinea Pigs 0 17 0 6 0 0 6 7 Hamsters 41 377 0 418 8. Rabbits 0 0 2283 472 1811 9. Non-human Primates 1764 0 0 27 0 27 10. Sheep 338 0 338 11. Pigs 0 0 0 0 0 0 0 12. Other Farm Animals 13. Other Animals 743 30 312 618 95 VOLES 0 14 11 GERBII S 0 3 ASSURANCE STATEMENTS

- Professionally acceptable standards governing the care, treatment, and use of animals, including appropriate use of anesthetic, analgesic, and tranquilizing drugs, prior to, during, and following actual research, teaching, testing, surgery, or experimentation were followed by this research facility.
- Each principal investigator has considered alternatives to painful procedures. 2.)
- This facility is adhering to the standards and regulations under the Act, and it has required that exceptions to the standards and regulations be specified and explained by the principal investigator and approved by the Institutional Animal Care and Use Committee (IACUC). A summary of all such exceptions is attached to this annual report. In addition to identifying the IACUC approved exceptions, this summary includes a brief explanation of the exceptions, as well as the species and number of animals affected. 3.)
- The attending veterinarian for this research facility has appropriate authority to ensure the provision of adequate veterinary care and to oversee the adequacy of other aspects of animal care and 4.)

CERTIFICATION BY HEADQUARTERS RESEARCH FACILITY OFFICIAL (Chief Executive Officer (C.E.O.) or Legally Responsible Institutional Official (I.O.))
I certify that the above is true, correct, and complete (7 U.S.C. Section 2143).

DATE SIGNED 11/30/2009

(b)(6), (b)(7)c

APHIS Form 7023 Site Addendum for FY: 2009

Registration Number: 57-R-0003 Customer ID Number: 896

Facility Business Address Information:

Emory University Woodruff Hlth Sciences Ctr, 1440 Clifton Rd Ne Atlanta, GA 30322

Telephone: (404) 727 3889

Facilities Site(s) Address Information:

Site Code(s):

002

(b)(2)High, (b)(7)f

Assigned Inspector: Christopher Nichols

003

(b)(2)High, (b)(7)f

Assigned Inspector: Christopher Nichols

004

(b)(2)High, (b)(7)f

Assigned Inspector: Christopher Nichols


001

(b)(2)High, (b)(7)f

Assigned Inspector: Christopher Nichols

DEC 0 1 2009

Annual Report to USDA Facility Locations Additional Site Addresses for Customer 896



Exceptions to Regulations and Standards

Use of Restraint Devices: Animals will be restrained for reasons of safety and scientific need. The type and length of restraint that is required for the research has been scientifically justified and then reviewed and approved by the Emory IACUC.

The IACUC reviewed and approved the use of restraint for the following protocols:

| Protocol # | Name of Study | # Animals Reported |
|--------------------------|--|-----------------------|
| 072-2009Y | Functional imaging of medial temporal lobe activity in awake primates: Inactivation, memory and emotion | 1 rhesus |
| 076-2007Y | Development of Reversible Inactivation Technique for the Study of Higher Cognitive Functions in Monkeys | 1 rhesus |
| 079-2007Y | PET Neuroimaging and Cocaine Neuropharmacology in Monkeys; PET in conscious monkeys | 39 rhesus |
| 081-2007Y | Regulation of motor function in Parkinson's disease; Effects of Cannabinoid Antagonists in the MPTP primate model of Parkinson's disease; Early cognitive deficits in Parkinson's disease: Functional and Morphological Evidence from non human primate model to patients with Parkinson's Disease | 10 rhesus |
| 095-2008Y | Development of a reversible deactivation, via cooling, technique to study higher cognitive functions in monkeys | 2 rhesus |
| 109-2009Y (070-2006Y) | Behavioral, neural and endocrine effects of differential rearing history in rhesus monkeys | 6 rhesus |
| 144-2007Y | Development of Medial Temporal Lobe Functions | 20 rhesus |
| 153-2008Y | Oxytocin and Nonhuman Primate Social Behavior | 7rhesus |
| 167-2009Y | Glutamate receptors: Novel targets for Parkinson's disease therapy | 7 rhesus |
| 173-2008Y | Neural Control of Visual-Vestibular Behavior | 5 rhesus |
| 178-2008Y | Local Field Potentials is the Basal Ganglia | 3 rhesus |
| 195-2008Y | Visual Processing and Smooth Eye Movements & Novel Immunotoxin and IGF Therapy for Strabismus | 6 rhesus |
| 204-2008Y | Neuronal Synchronization in the Medial Temporal Lobe and Memory Formation | 6 rhesus |
| 207-2007Y | Genetic Inhibition of BDNF Receptor in Macaque Amygdala | 3 rhesus |
| 207-2008Y | Neural Mechanisms for Smooth Pursuit Adaptation | 2 rhesus |
| 212-2006Y | GABA-B Receptors and Parkinson's Disease | 1 rhesus |
| 217-20066Y | Function of Dopamine in the Primate Substantia Nigra | 3 rhesus |
| 260-2008Y | Hippocampal Control of Working Memory: Inactivation and PET in Monkeys | 3 rhesus |
| 264-2007Y | Binocular Coordination of Eye Movements; Surgical treatment of Strabismus in Juvenile Monkeys | 10 rhesus |
| 267-2008Y | Developing a Nonhuman Primate Model of Alzheimer's Disease | 1 rhesus |
| 305-2008Y | Cocaine Use and Monoamine Function in Nonhuman Primates; Monoamine Transporters and Nonhuman Primate Cocaine Use | 34 squirrel monkeys |

DEC 0 1 2009

Social Enrichment: Animals are exempted from normal social enrichment for various periods of time as needed to conduct the experiments. The reasons for the exemptions from social enrichment and the length of time that animals are exempted have been scientifically justified and then reviewed and approved by the Emory IACUC.

The IACUC granted exemptions from social housing to allow singly housed animals for the following

protocols:

| Protocol# Name of Study | | # Animals Reported | |
|-------------------------|--|--------------------------|--|
| 005-2008Y | Transplant Tolerance in Non-Human Primates | 98 rhesus | |
| 013-2009Y | Neural Correlates of Primate Action and Emotion Perception | 5 chimps | |
| 027-2009Y | Infant Immunoprophylaxis Against A primate Lentivirus | 13 pigtails 15 rhesus | |
| 061-2007Y | SHIV Transmission through Oral Versus Other Mucosae | 13 rhesus | |
| 062-2008Y | Peripartum Changes in Monoamine Activity | 1 rhesus | |
| 067-2008Y | Does CRH Receptor Antagonism Reduce Self-Injurious Behavior and Improve Gastrointestinal Health in Rhesus Macaques | 9 rhesus | |
| 068-2007Y | Relationship Between Serum and CSF Drug Levels and Central D2 Occupancy for Two Atypical Antipsychotics | 2 rhesus | |
| 072-2009Y | Functional imaging of medial temporal lobe activity in awake primates: Inactivation, memory and emotion | 1 rhesus | |
| 076-2007Y | Development of Reversible Inactivation Technique for the Study of Higher Cognitive Functions in Monkeys | 1 rhesus | |
| 079-2007Y | PET Neuroimaging and Cocaine Neuropharmacology in Monkeys; PET in conscious monkeys | 39 rhesus | |
| 081-2007Y | Regulation of motor function in Parkinson's disease; Effects of Cannabinoid Antagonists in the MPTP primate model of Parkinson's disease; Early cognitive deficits in Parkinson's disease: Functional and Morphological Evidence from non human primate model to patients with Parkinson's Disease | 10 rhesus | |
| 088-2007Y | Evaluation of anti-HIV Interventions for the Prevention of SHIV Transmission in Pig-tailed Macaques | 22 rhesus | |
| 093-2008Y | Morphine, Innate Immunity and Early SIV Neuropathogenesis | 4 rhesus | |
| 094-2007Y | Neuropsychology of Primate Social Cognition | 8 rhesus | |
| 095-2008Y | Development of a reversible deactivation, via cooling, technique to study higher cognitive functions in monkey | 2 rhesus | |
| 098-2008Y | Pre-Clinical Non-human Primate Islet Allotransplantation Model for Tolerance Induction Testing with CTLA-4-Ig (Abatacept), LFA-3-Ig (Alefacept), and Sirolimus | 26 rhesus | |
| 112-2007Y | Orbitofrontal-limbic ontogeny and early dysfunction; The integration of multisensory social cues and its neural basis in monkeys | 16 rhesus | |
| 114-2008Y | Immune Activation and AIDS Pathogenesis in SIV-infected Non-Human Primates | 8 sooty | |
| 119-2007Y | Use of Osteoinductive Factors (DBM) to Enhance Spine Fusion / Osteotech | 6 rhesus | |
| 142-2007Y | Project 3: Attenuated Listeria Vectors as an AIDS Vaccine in Macaques | 23 rhesus | |
| 142-2008Y | Innate Immunity and Affects of Macrophage Depletion in SIV- Infected Non-Human Primates | 1 rhesus | |

| 144-2007Y | n previous page | 10 rhesus |
|-----------|--|----------------------|
| | Development of Medial Temporal Lobe Functions | 20 rhesus |
| 149-2007Y | PD-1 Blockade as a Therapy for SIV/AIDS | |
| 153-2008Y | Oxytocin and Nonhuman Primate Social Behavior | 3 rhesus |
| 167-2009Y | Glutamate Receptors: Novel Targets for Parkinson's Disease Therapy | 7 rhesus |
| 173-2008Y | Neural Control of Visual-Vestibular Behavior | 5 rhesus |
| 176-2007Y | Determinants of Vaccine-Induced Memory T Cell Development | 21 rhesus |
| 177-2006Y | Poxvirus Immunity and DNA/MVA HIV Vaccines | 4 rhesus |
| 178-2008Y | Local Field Potentials is the Basal Ganglia | 3 rhesus |
| 192-2007Y | Creating a Non-Human Primate Model of Graft-Versus Host Disease: Determining Mechanism and Assessing Novel Therapeutics | 18 rhesus |
| 195-2008Y | Visual Processing and Smooth Eye Movements & Novel Immunotoxin and IGF Therapy for Strabismus | 15 rhesus |
| 198-2008Y | Non-Human Primate Models of Malarial Anemia | 17 rhesus |
| 203-2007Y | Development of a Monkey Dystonia Model | 3 rhesus |
| 208-2007Y | Non-human Primate Renal Transplantation as a Pre-clinical model for testing Genzyme 29155 for Allospecific Tolerance Induction | 4 rhesus |
| 212-2006Y | GABA-B Receptors and Parkinson's Disease | 2 rhesus |
| 213-2006Y | The Thalamostriatal System as a Target for Tourette's Syndrome | 1 rhesus |
| 217-2006Y | Function of Dopamine in the Primate Substantia Nigra | 2 rhesus |
| 224-2007Y | Modulating HIV Immunity with Dendritic Cells | 40 rhesus |
| 240-2008Y | Immune Function and Biodefense in Children, Elderly and Immunocompromised Populations; Project 3 | 21 rhesus |
| 242-2007Y | Neurology of Memory in the Non Human Primate | 12 cynos |
| 247-2007Y | Early Innate Immune Response in Dengue Virus Infection | 3 rhesus |
| 254-2007Y | Studies of the natural SIV infection of sooty mangabeys | 2 sooty 15 rhesus |
| 255-2008Y | Focal Alzheimer APP Transgene Expression in Rhesus Macaques | 2 rhesus |
| 256-2008Y | Molecular Evolution of Multiply Deleted SIV in Vivo | 10 rhesus |
| 259-2007Y | Molecular Mechanisms of Antigenic Variation in Malaria | 14 rhesus |
| 260-2007Y | PD-1 Ligand Blockade as a therapy for SIV | 22 rhesus |
| 260-2008Y | Hippocampal Control of Working Memory: Inactivation and PET in Monkeys | 3 rhesus |
| 261-2008Y | Vaccination Against Mucosal HIV Clade C Transmission | 72 rhesus |
| 264-2007Y | Binocular Coordination of Eye Movements; Surgical treatment of Strabismus in Juvenile Monkeys | 10 rhesus |
| 285-2008Y | Memory and Regulatory T Cells Following T Cell Depletion in Transplantation | 13 rhesus |
| 305-2008Y | Cocaine Use and Monoamine Function in Nonhuman Primates; Monoamine Transporters and Nonhuman Primate Cocaine Use | 34 squirrel monkey |

Year 2009 Annual Report for Research Facilities, Emory University, Atlanta, GA Attachment 2 to APHIS Form 7023 Page 4

Food/Water Restriction: The following protocols had some type of food or water restriction. Food and/or water would be withheld because of the scientific needs of the research being conducted. The food and/or water restriction have been scientifically justified in the IACUC protocol and then reviewed and approved by the Emory IACUC.

The IACUC granted exceptions for food/water restriction for the following protocols:

| Protocol # | Name of Study | # Animals Used |
|------------|---|----------------|
| 004-2006Y | Effects of Viewing Distance on Eye Growth and Refractive Development | 8 rhesus |
| 094-2007Y | Neuropsychology of Primate Social Cognition | 8 rhesus |
| 153-2008Y | Oxytocin & Nonhuman Primate Social Behavior | 7 rhesus |
| 204-2008Y | Neuronal Synchronization in the Medial Temporal Lobe and Memory Formation | 6 rhesus |
| 207-2008Y | Neural Mechanisms for Smooth Pursuit Adaptation | 2 rhesus |

Summary of Studies (Animal) Listed in Column E

Prairie vole pups were used to test maternal behavior. Replacement of pups by objects or anesthetized pups would not trigger the appropriate maternal responses from the adult subjects. The animals were under continuous observation during the test. The IACUC reviewed and approved this Class E procedure for the following protocols:

| Protocol # | Name of Study | # Animals Used |
|------------|--------------------------------|----------------|
| 060-2007Y | Oxytocin and Social Attachment | 30 voles |

The study below was reviewed and approved by the IACUC to allow for the withholding of analgesic agents based upon the scientific justification that fever (nonsteroidal inflammatory agents) and immune function (opioids) may be inhibited.

| Protocol # | Name of Study | # Animals Used |
|------------|--|-----------------|
| 204-2007 | Pichinde virus infection of guinea pigs as an animal model for Lassa fever | 273 Guinea Pigs |